You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020190036
Dec 20204609
Jan 20213805
Feb 20216108
Mar 2021124024
Apr 2021104017
May 202126021
Jun 20210015
Jul 2021008
Aug 20210021
Sep 20210017
Oct 2021102025
Nov 2021104026
Dec 20216609
Jan 202284011
Feb 20224807
Mar 202280016
Apr 20226607
May 202256027
Jun 202240020
Jul 20222807
Aug 20223209
Sep 202238016
Oct 20222206
Nov 20225406
Dec 20224407
Jan 202352017
Feb 20235007
Mar 202360010
Apr 20235805
May 20234605
Jun 202332011
Jul 20233405
Aug 202358013
Sep 20236409
Oct 202319409
Nov 202333004
Dec 20234805
Jan 20241801
Feb 20242404
Mar 20246807
Apr 20244207
May 202440011
Jun 20242203
Jul 20243604
Aug 20244007
Sep 20244206
Oct 20242206
Nov 20242406
Dec 20242403
Jan 20252607
Feb 202510011
Mar 2025009
Apr 20250011
May 20250016
Jun 2025006
Total29170605